Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: <i>In vivo</i> Study. A more efficient combination

Sapalidis, Konstantinos; Pavlidis, Efstathios T; Laskou, Styliani; Katsaounis, Athanasios; Koulouris, Charilaos; Giannakidis, Dimitrios; Mantalovas, Stylianos; Huang, Haidong; Bai, Chong; Wen, Yuting; Wang, Li; Sardeli, Chrysanthi; Amaniti, Aikaterini; Karapantzos, Ιlias; Karapantzou, Chrysanthi; Hohenforst-Schmidt, Wolfgang; Konstantinou, Fotis; Κεσίσογλου, Ισαάκ; Benhanseen, Naim

doi:10.7150/jca.24782

Cited by 4 publications

(4 citation statements)

References 43 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again abscess formation has been observed in a previous case series due to high PD-L1 expression and it is common in large NSCLC lesions [161]. There are two more studies that support that local aerosol administration of immunotherapy has a favorable effect and could be used alternatively in NSCLC for selected patients [162,163].…”

Section: Immunotherapymentioning

confidence: 70%

Airway local endoscopic pharmacological treatment; current applications and future concepts

Kosmıdis¹,

Sapalidis²,

Hohenforst-Schmidt³

et al. 2022

Front. Biosci. (Landmark Ed)

Self Cite

View full text Add to dashboard Cite

Introduction:Local treatment of the airways and lung parenchyma has been used in clinical practice for several years for a variety of diseases. Methods: A variety of endoscopic tools for local treatment exist, especially for treating malignancies. Using these endoscopic tools, one can administer drugs specifically designed for the airways. Discussion: This article presents all locally administered treatment options and provides useful insights for future local endoscopically applied treatments.

show abstract

Section: Immunotherapymentioning

confidence: 70%

Airway local endoscopic pharmacological treatment; current applications and future concepts

Kosmıdis¹,

Sapalidis²,

Hohenforst-Schmidt³

et al. 2022

Front. Biosci. (Landmark Ed)

Self Cite

View full text Add to dashboard Cite

show abstract

“…In another study, a combination of CIS and nivolumab was used for nebulized inhalation therapy. The results showed that administering immunotherapy before CIS treatment extended the survival of mice and reduced lung metastasis ( 128 ). However, it is noteworthy that the model used in that study involved subcutaneous tumor implantation in the foot, and further observation is needed to evaluate the direct therapeutic effect on in situ lung cancer.…”

Section: Preclinical Application Of Micron/nddsmentioning

confidence: 99%

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

Xie,

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Lung cancer represents a marked global public health concern. Despite existing treatment modalities, the average 5-year survival rate for patients with patients with lung cancer is only ~20%. As there are numerous adverse effects of systemic administration routes, there is an urgent need to develop a novel therapeutic strategy tailored specifically for patients with lung cancer. Non-invasive aerosol inhalation, as a route of drug administration, holds unique advantages in the context of respiratory diseases. Nanoscale materials have extensive applications in the field of biomedical research in recent years. The present study provides a comprehensive review of the classification, applications summarized according to existing clinical treatment modalities for lung cancer and challenges associated with inhalable micron/nanoparticle drug delivery systems (DDSs) in lung cancer. Achieving localized treatment of lung cancer preclinical models through inhalation is deemed feasible. However, further research is required to substantiate the efficacy and long-term safety of inhalable micron/nanoparticle DDSs in the clinical management of lung cancer.

show abstract

“…Non-small cell lung cancer (NSCLC) remains the leading cause of mortality from cancer, and surgery combined with chemotherapy has increased the long-term survival rate of patients with NSCLC (1). Chemotherapy is effective by triggering the death of tumor cells, but the occurrence of drug resistance can limit its efficacy (2).…”

Section: Introductionmentioning

confidence: 99%

LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy

Huang

Chen

Zheng³

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

The aim of the present study was to determine the effect of the long non-coding RNA (lncRNA) bladder cancer-associated transcript 1 (BLACAT1) in chemoresistance of non-small cell lung cancer (NSCLC) cells. Expression of lncRNA BLACAT1, microRNA (miR)-17, autophagy-related protein 7 (ATG7), multidrug-resistance protein 1 (MRP1), and the autophagy-associated proteins light chain 3 (LC3)-II/LC3-I and Beclin 1 were detected using the reverse transcription-quantitative polymerase chain reaction and western blot analysis. Cell viability was determined using an MTT assay. The interaction between BLACAT1 and miR-17 was determined using RNA immunoprecipitation and RNA pull-down assays. A cisplatin (DDP)-resistant NSCLC cell A549/DDP xenograft model in nude mice was established to investigate the effect of BLACAT1 on the chemoresistance of NSCLC cells. Compared with in DDP-sensitive NSCLC cells, expression of BLACAT1, ATG7, MRP1, LC3-II/LC3-I and Beclin 1 was significantly upregulated in DDP-resistant NSCLC cells, whereas miR-17 was downregulated in DDP-resistant NSCLC cells. Short interfering RNA against BLACAT1 decreased the viability of DDP-resistant NSCLC cells. In addition, BLACAT1 interacted with miR-17, and negatively regulated miR-17. BLACAT1 promoted ATG7 expression through miR-17, and facilitated autophagy and promoted chemoresistance of NSCLC cells through miR-17/ATG7. Finally, in vivo experiments indicated that inhibition of BLACAT1 ameliorated the chemoresistance of NSCLC. BLACAT1 was upregulated in DDP-resistant NSCLC cells, and promoted autophagy and chemoresistance of NSCLC cells through the miR-17/ATG7 signaling pathway.

show abstract

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination

Cited by 4 publications

References 43 publications

Airway local endoscopic pharmacological treatment; current applications and future concepts

Airway local endoscopic pharmacological treatment; current applications and future concepts

A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)

LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy

Contact Info

Product

Resources

About